Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.88 |
| ▸ | NPC1 | O15118 | 6/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | TP53 | P04637 | 1/20 | 0.88 |
| ▸ | PKM | P14618 | 1/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15727520 | 0.93 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL1013974 | 0.93 | RAB9A (0.94) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL13860606 | 0.89 | RAB9A (0.76) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL18038915 | 0.85 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL18717608 | 0.84 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL18717607 | 0.84 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL13974961 | 0.84 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL2557636 | 0.83 | NPC1 (0.63) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL18692959 | 0.83 | RAB9A (0.67) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL18717606 | 0.83 | RAB9A (0.67) | RAB9ASMN1; SMN2NPC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20240400551-A1 | NEK7 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2021067967-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | CAL POLY CORPORATION | 2021-04-08 | — | — | US | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| CN-108218869-B | Synthesis method of pyrazolo [3,4-b ] pyrrolo [3,4-d ] pyridine derivative | 苏州大学 | 2020-06-05 | — | — | CN | disclosed |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1831228-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006068591-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| EP-0839144-B1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL GMBH (DE) | 2001-09-19 | — | — | EP | disclosed |
| US-6114334-A | CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
| EP-0839144-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003067-A1 | PIPERAZINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | CHRM2, CHRNA1, CHRM1 | RAB9A 1005/4885SMN1; SMN2 1451/4885NPC1 970/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | RAB9A 3477/4885SMN1; SMN2 3670/4885NPC1 348/4885 |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | PNPO, NOX3, G6PD | RAB9A 1213/4885SMN1; SMN2 4360/4885NPC1 2176/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | RAB9A 2475/4885SMN1; SMN2 2313/4885NPC1 3749/4885 |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | PNPO, NOX3, G6PD | RAB9A 1213/4885SMN1; SMN2 4360/4885NPC1 2176/4885 |
| US-20240400551-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | RAB9A 2502/4885SMN1; SMN2 3294/4885NPC1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.